CyanVac secures funding for Phase IIb intranasal Covid-19 vaccine trial
In preclinical studies, CVXGA was found to be immunogenic, protective, and could prevent virus transmission.
14 June 2024
14 June 2024
In preclinical studies, CVXGA was found to be immunogenic, protective, and could prevent virus transmission.
Recent trends highlight a surge in demand for mass market medicines. This increase is driven by lessons from the Covid-19 pandemic, when vaccines had to be made available quickly in large quantities, but also from the ongoing need for diabetes or weight loss medication.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.